ID

27764

Description

Study part: Follow- Up. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Keywords

  1. 11/28/17 11/28/17 -
Copyright Holder

Charité – University of medicine Berlin

Uploaded on

November 28, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Follow- Up SirTac NCT02936388

Follow- Up

  1. StudyEvent: ODM
    1. Follow- Up
Follow- Up
Description

Follow- Up

Alias
UMLS CUI-1
C1522577
Patienten-ID:
Description

Patient-ID

Data type

text

Alias
UMLS CUI [1]
C2348585
Random. Nr.:
Description

randomization number

Data type

text

Alias
UMLS CUI [1,1]
C1300638
UMLS CUI [1,2]
C0034656
Follow-up Visite Nr.:
Description

visit number

Data type

integer

Alias
UMLS CUI [1]
C1549755
Durchgeführt am
Description

visit date

Data type

date

Alias
UMLS CUI [1]
C1320303
Allgemeiner Zustand:
Description

general condition

Data type

text

Alias
UMLS CUI [1]
C1142435
Krankheitsverlauf (Folgetherapien, relevante Ereignisse usw.):
Description

course of a disease

Data type

text

Alias
UMLS CUI [1]
C0242656
Späte Toxizitäten:
Description

Späte Toxizitäten:

Alias
UMLS CUI-1
C0013221
Code
Description

laut CTCAE-Kriterien

Data type

text

Alias
UMLS CUI [1]
C0805701
Art der Toxizität
Description

drug toxicity

Data type

text

Alias
UMLS CUI [1]
C0013221
Grad
Description

laut CTCAE-Kriterien

Data type

text

Alias
UMLS CUI [1,1]
C0441800
UMLS CUI [1,2]
C0013221
Keine Toxizität zu dokumentieren
Description

Documentation drug toxicity

Data type

boolean

Alias
UMLS CUI [1,1]
C0920316
UMLS CUI [1,2]
C0013221
Kommentar:
Description

comment

Data type

text

Alias
UMLS CUI [1]
C0947611
Ausgefüllt/bestätigt am:
Description

date

Data type

date

Alias
UMLS CUI [1]
C0011008
Name Prüfarzt
Description

investigator name

Data type

text

Alias
UMLS CUI [1]
C2826892
Unterschrift Prüfarzt
Description

investigator signature

Data type

text

Alias
UMLS CUI [1]
C2346576

Similar models

Follow- Up

  1. StudyEvent: ODM
    1. Follow- Up
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Follow- Up
C1522577 (UMLS CUI-1)
Patient-ID
Item
Patienten-ID:
text
C2348585 (UMLS CUI [1])
randomization number
Item
Random. Nr.:
text
C1300638 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
visit number
Item
Follow-up Visite Nr.:
integer
C1549755 (UMLS CUI [1])
visit date
Item
Durchgeführt am
date
C1320303 (UMLS CUI [1])
general condition
Item
Allgemeiner Zustand:
text
C1142435 (UMLS CUI [1])
course of a disease
Item
Krankheitsverlauf (Folgetherapien, relevante Ereignisse usw.):
text
C0242656 (UMLS CUI [1])
Item Group
Späte Toxizitäten:
C0013221 (UMLS CUI-1)
Code
Item
Code
text
C0805701 (UMLS CUI [1])
drug toxicity
Item
Art der Toxizität
text
C0013221 (UMLS CUI [1])
Grade drug toxicity
Item
Grad
text
C0441800 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
Documentation drug toxicity
Item
Keine Toxizität zu dokumentieren
boolean
C0920316 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
comment
Item
Kommentar:
text
C0947611 (UMLS CUI [1])
date
Item
Ausgefüllt/bestätigt am:
date
C0011008 (UMLS CUI [1])
investigator name
Item
Name Prüfarzt
text
C2826892 (UMLS CUI [1])
investigator signature
Item
Unterschrift Prüfarzt
text
C2346576 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial